Taigen Biopharmaceuticals Holdings Ltd (4157) - Net Assets
Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) has net assets worth NT$892.68 Million TWD (≈ $28.12 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.01 Billion ≈ $31.93 Million USD) and total liabilities (NT$120.70 Million ≈ $3.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4157 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$892.68 Million |
| % of Total Assets | 88.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | 144.77% |
| 10-Year Change | 145.09% |
| Growth Volatility | 136.23 |
Taigen Biopharmaceuticals Holdings Ltd - Net Assets Trend (2010–2024)
This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Taigen Biopharmaceuticals Holdings Ltd (4157) total assets for the complete picture of this company's asset base.
Annual Net Assets for Taigen Biopharmaceuticals Holdings Ltd (2010–2024)
The table below shows the annual net assets of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2024. For live valuation and market cap data, see 4157 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.08 Billion ≈ $34.10 Million |
-3.27% |
| 2023-12-31 | NT$1.12 Billion ≈ $35.25 Million |
+15.35% |
| 2022-12-31 | NT$970.03 Million ≈ $30.56 Million |
-22.63% |
| 2021-12-31 | NT$1.25 Billion ≈ $39.50 Million |
+183.52% |
| 2020-12-31 | NT$442.18 Million ≈ $13.93 Million |
-45.76% |
| 2019-12-31 | NT$815.18 Million ≈ $25.68 Million |
-25.44% |
| 2018-12-31 | NT$1.09 Billion ≈ $34.45 Million |
-23.25% |
| 2017-12-31 | NT$1.42 Billion ≈ $44.88 Million |
+110.84% |
| 2016-12-31 | NT$675.62 Million ≈ $21.29 Million |
+52.99% |
| 2015-12-31 | NT$441.60 Million ≈ $13.91 Million |
-48.18% |
| 2014-12-31 | NT$852.14 Million ≈ $26.85 Million |
+454.15% |
| 2013-12-31 | NT$153.77 Million ≈ $4.84 Million |
-58.75% |
| 2012-12-31 | NT$372.80 Million ≈ $11.75 Million |
-27.36% |
| 2011-12-31 | NT$513.21 Million ≈ $16.17 Million |
+111.96% |
| 2010-12-31 | NT$-4.29 Billion ≈ $-135.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Taigen Biopharmaceuticals Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 540260500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$615.26 Million | 56.85% |
| Other Components | NT$467.07 Million | 43.15% |
| Total Equity | NT$1.08 Billion | 100.00% |
Taigen Biopharmaceuticals Holdings Ltd Competitors by Market Cap
The table below lists competitors of Taigen Biopharmaceuticals Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KOSKISEN OYJ EO 1
F:EZ8
|
$222.48 Million |
|
Taliworks Corporation Bhd
KLSE:8524
|
$222.69 Million |
|
Iron Force Industrial Co Ltd
TW:2228
|
$222.70 Million |
|
Dong Nai Port JSC
VN:PDN
|
$222.73 Million |
|
Caisse régionale de Crédit Agricole Mutuel Atlantique Vendée
PA:CRAV
|
$222.38 Million |
|
Kwong Lung Enterprise Co Ltd
TWO:8916
|
$222.38 Million |
|
TriSalus Life Sciences Inc.
NASDAQ:TLSI
|
$222.34 Million |
|
Acsion Ltd
JSE:ACS
|
$222.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taigen Biopharmaceuticals Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,118,898,000 to 1,082,326,000, a change of -36,572,000 (-3.3%).
- Net loss of 38,583,000 reduced equity.
- Other comprehensive income decreased equity by 103,538,000.
- Other factors increased equity by 105,549,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-38.58 Million | -3.56% |
| Other Comprehensive Income | NT$-103.54 Million | -9.57% |
| Other Changes | NT$105.55 Million | +9.75% |
| Total Change | NT$- | -3.27% |
Book Value vs Market Value Analysis
This analysis compares Taigen Biopharmaceuticals Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | NT$-7.60 | NT$9.92 | x |
| 2011-12-31 | NT$0.88 | NT$9.92 | x |
| 2012-12-31 | NT$0.63 | NT$9.92 | x |
| 2013-12-31 | NT$0.24 | NT$9.92 | x |
| 2014-12-31 | NT$1.22 | NT$9.92 | x |
| 2015-12-31 | NT$0.63 | NT$9.92 | x |
| 2016-12-31 | NT$0.95 | NT$9.92 | x |
| 2017-12-31 | NT$1.99 | NT$9.92 | x |
| 2018-12-31 | NT$1.53 | NT$9.92 | x |
| 2019-12-31 | NT$1.14 | NT$9.92 | x |
| 2020-12-31 | NT$0.62 | NT$9.92 | x |
| 2021-12-31 | NT$1.75 | NT$9.92 | x |
| 2022-12-31 | NT$1.35 | NT$9.92 | x |
| 2023-12-31 | NT$1.56 | NT$9.92 | x |
| 2024-12-31 | NT$1.51 | NT$9.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taigen Biopharmaceuticals Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.61%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.08x
- Recent ROE (-3.56%) is above the historical average (-42.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -15333.54% | 0.01x | 0.00x | NT$-1.86 Billion |
| 2011 | 8.35% | 18.98% | 0.37x | 1.19x | NT$-8.48 Million |
| 2012 | -125.64% | -1158.25% | 0.06x | 1.97x | NT$-505.68 Million |
| 2013 | -281.06% | -618.52% | 0.14x | 3.16x | NT$-447.57 Million |
| 2014 | -47.38% | -385.97% | 0.10x | 1.29x | NT$-488.93 Million |
| 2015 | -93.52% | -529.45% | 0.12x | 1.42x | NT$-457.15 Million |
| 2016 | -37.01% | -171.23% | 0.18x | 1.22x | NT$-317.60 Million |
| 2017 | 52.40% | 134.92% | 0.36x | 1.07x | NT$603.93 Million |
| 2018 | -31.39% | -1158.79% | 0.02x | 1.09x | NT$-452.54 Million |
| 2019 | -36.27% | -1455.57% | 0.02x | 1.16x | NT$-377.20 Million |
| 2020 | -91.55% | -1728.37% | 0.04x | 1.26x | NT$-449.04 Million |
| 2021 | 61.87% | 59.92% | 0.93x | 1.11x | NT$650.25 Million |
| 2022 | -24.45% | -654.61% | 0.03x | 1.08x | NT$-334.17 Million |
| 2023 | 12.22% | 111.04% | 0.10x | 1.10x | NT$24.84 Million |
| 2024 | -3.56% | -25.61% | 0.13x | 1.08x | NT$-146.82 Million |
Industry Comparison
This section compares Taigen Biopharmaceuticals Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,834,063,600
- Average return on equity (ROE) among peers: 8.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taigen Biopharmaceuticals Holdings Ltd (4157) | NT$892.68 Million | 0.00% | 0.14x | $222.47 Million |
| Apex Biotechnology Corp (1733) | $1.82 Billion | 10.00% | 0.38x | $89.12 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $2.09 Billion | 6.26% | 0.71x | $188.46 Million |
| Panion & BF Biotech Inc (1760) | $301.62 Million | -13.03% | 1.86x | $175.04 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.86 Billion | 16.54% | 0.54x | $67.13 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $969.06 Million | 16.12% | 0.26x | $99.19 Million |
| Level Biotechnology (3118) | $559.91 Million | 11.58% | 0.48x | $34.25 Million |
| GenMont Biotech Inc (3164) | $1.50 Billion | 3.81% | 0.13x | $47.96 Million |
| Medigen Biotechnology (3176) | $6.43 Billion | -0.82% | 0.28x | $145.49 Million |
| Sagittarius Life Science (3205) | $1.21 Billion | 22.13% | 0.17x | $120.24 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.60 Billion | 9.31% | 0.28x | $96.22 Million |
About Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more